Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
TAGAMET HB 200 is a cimetidine-based oral suspension approved in 1999 for over-the-counter and prescription use in gastric acid-related conditions. The drug is a small-molecule H2-receptor antagonist that reduces stomach acid production. It represents a mature, well-established therapeutic category with broad patient accessibility.
Product is in mature/declining phase with moderate competitive pressure (30/100), limiting team expansion but requiring strong lifecycle management expertise.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
TAGAMET HB 200 offers limited career growth opportunities due to approaching loss of exclusivity and minimal linked job postings. Professionals joining this team should expect to focus on defensive market strategies, cost management, and operational efficiency rather than growth initiatives.
Worked on TAGAMET HB 200 at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.